1. Pomerantz LLP is investigating GALT for potential securities fraud. 2. Investors can join the class action related to this investigation. 3. GALT's stock price dropped 28.9% after FDA communication about belapectin. 4. FDA's response indicated unresolved key aspects in trial design. 5. Galectin will pursue further communication regarding their clinical trial plans.
FAQ
Why Very Bearish?
The significant stock price drop (28.9%) reflects severe market concern over potential fraud and unresolved FDA issues. Historically, such investigations have led to long-term investor distrust and price depreciation.
How important is it?
Given the nature of the investigation and its impact on investor sentiment, the likelihood of significant price action is high. Investors may exit in haste, impacting GALT's market performance.
Why Short Term?
The immediate reaction to the FDA's feedback and the investigation suggests short-term volatility. Previous instances where companies faced fraud allegations saw quick declines before potential recoveries if cleared.
Investor Alert: Pomerantz Law Firm Investigates Galectin Therapeutics Inc. (NASDAQ: GALT)
Pomerantz LLP is currently investigating claims on behalf of investors of Galectin Therapeutics Inc. (NASDAQ: GALT). This legal inquiry focuses on whether Galectin and its officers or directors may have engaged in securities fraud or other unlawful business practices. Interested investors are encouraged to reach out to Danielle Peyton at 646-581-9980, ext. 7980 for more information.
Background on Regulatory Updates
On December 19, 2025, Galectin Therapeutics announced that the U.S. Food and Drug Administration (FDA) provided a written response to the company’s Type C meeting request regarding the development of belapectin, an investigational galectin-3 inhibitor. The FDA converted the initial request for an in-person meeting to a written format. Despite some alignment with the FDA on the proposed patient population for a registration trial, significant elements of the trial design remain unresolved.
Market Impact Following FDA Communication
The announcement led to a notable decline in Galectin's stock price. Following the release of this news, shares of GALT dropped $1.78, equivalent to a 28.9% decrease, closing at $4.38 per share on the same day. This stark response from the market highlights the sensitivity of investors to regulatory communications surrounding clinical trials and drug approvals.
Pomerantz LLP: A Leader in Securities Litigation
Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation. With offices across major cities—including New York, Chicago, Los Angeles, London, Paris, and Tel Aviv—the firm has a legacy of fighting for the rights of victims of securities fraud and corporate misconduct. Established by the late Abraham L. Pomerantz, often referred to as the dean of the class action bar, the firm has successfully recovered numerous multimillion-dollar awards for class members over its 85-year history.
Contact Information
For further inquiries regarding the investigation into Galectin Therapeutics Inc. (NASDAQ: GALT), investors can contact:
- Name: Danielle Peyton
- Firm: Pomerantz LLP
- Email: danielle.peyton@pomlaw.com
- Phone: 646-581-9980, ext. 7980
Important Disclaimers
This communication is classified as attorney advertising. Past results do not guarantee future similar outcomes. For more information, visit www.pomlaw.com.